Attensi and SAP SuccessFactors Enter into a Strategic Partnership to Revolutionize Learning and Development
SAP SuccessFactors is the leading human capital management (HCM) solution, helping customers stay ahead of the competition to attract, develop and retain the best employees and ensuring a holistic employee journey throughout the employee lifecycle. Attensi delivers groundbreaking gamification and simulation-based training. Through this collaboration, the partners will offer an innovative learning experience using, among other approaches, gaming technology and competitive elements. The collaboration means that the two platforms work together to ensure a unified user experience and natural data flow, with the allocation and follow-up of learning as well as competence and development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006137/en/
Attensi and SAP SuccessFactors enter into a strategic partnership to revolutionize learning and development. (Graphic: Business Wire)
“We are currently in an era of change and rapid technological development where learning and competence development are becoming increasingly more important to businesses. It is incredibly rewarding to be able to embrace successful HR tech "scale-ups" such as Attensi, so that we can offer innovative technology like this as part of our open ecosystem to the benefit of our rapidly growing customer community."
– Jens Conradi, Sales Director, SAP SuccessFactors
The solutions that Attensi offers combines advanced 3D simulation with deep insight into human behavior and psychology. Employees encounter virtual scenarios that are individually adapted to the individual business and bring to life actual experiences from the organization's reality. As employees evolve, they get educational, personalized feedback, and scores on their results. In addition, Attensi allows you to engage employees with automated campaigns and communication. As a manager, you can easily follow your team in real time, provide feedback to your employees, and measure the impact of the learning.
"The collaboration with SAP SuccessFactors is of strategic importance to Attensi. We can now offer customers who use SuccessFactors a seamless learning experience where the best elements of SuccessFactors play together with Attensi's solutions and platform. This enables even better and faster competence development and behavioral training for all the millions of employees in the companies that use SuccessFactors."
– Trond Aas, CEO, Attensi
"This is a major milestone in the development of the Attensi Technology Platform! Having achieved all qualifications required by SAP to enter a partnership recognizes Attensi as a top player in the field. We are extremely excited to provide our users access to world-leading learning technology delivered seamlessly in SAP SuccessFactor's global platform."
– Anne Lise Waal, CTO & COO, Attensi
About Attensi
Attensi delivers next generation simulation-based learning technology based on game mechanics and behavioral psychology that impacts KPIs and drives change in large organizations. Attensi is headquartered in Oslo, Norway, with offices in UK, USA and Germany and has delivered over 500 simulation solutions in over 20 languages to a global user base.
About SAP SuccessFactors
SAP's solutions help more than 400,000 customers around the world work better together using business insights more efficiently. Originally known for ERP software, SAP has evolved to become the market leader in business applications and related services for data, analytics, and intelligent technologies.
SAP SuccessFactors is a cloud-based, holistic HR solution that supports the entire employee journey including recruitment, onboarding, talent development, payroll, and HR analytics. SAP SuccessFactors provides personalized user experiences that facilitate competence development and more engaged and productive employees. SAP SuccessFactors has 200 million users in over 7,000 businesses worldwide, of which over 40 Norway. The solution is located in 101 countries and supports 43 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006137/en/
Contact information
Allison Knight for Attensi
attensi@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom